We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
Turnover
22.92%
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+19.23%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$140M
AUM Growth
+$21.9M
(+19%)
Cap. Flow
+$4.55M
Cap. Flow
% of AUM
3.25%
Top 10 Holdings %
Top 10 Hldgs %
48%
Holding
83
New
9
Increased
22
Reduced
16
Closed
8
Avg Time Held
1.4
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$2.79M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$2.7M |
| 3 |
Dermira, Inc.
DERM
|
+$1.44M |
| 4 |
SANGAMO THERAPEUTICS INC
SGMO
|
+$1.44M |
| 5 |
Minerva Neurosciences
NERV
|
+$1.42M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$2.61M |
| 2 |
Tvardi Therapeutics
TVRD
|
+$1.75M |
| 3 |
Novadaq Technologies Inc.
NVDQ
|
+$747K |
| 4 |
MetaVia Inc
MTVA
|
+$725K |
| 5 |
Abeona Therapeutics
ABEO
|
+$338K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.55% |
| 2 | Miscellaneous | 7.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
CASC
51
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $436K | 0.31% |
117,310
-67,949
| -37% | -$270K |
2017 Q1
1 quarter
|
|
|
52
MetaVia Inc
MTVA
$8.3M
| – | – |
-1
| Closed | -$725K | – |
|
53
DELISTED
Masimo
MASI
| $388K | 0.28% |
4,250
+750
| +21% | +$68.9K |
2013 Q2
16 quarters
|
|
|
SRRA
54
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $310K | 0.22% |
6,625
| – | – |
2017 Q1
1 quarter
|
|
|
NTUS
55
DELISTED
Natus Medical Inc
NTUS
| $295K | 0.21% |
+7,900
| New | +$285K |
2017 Q2
0 quarters
|
|
|
HSTO
56
DELISTED
Histogen Inc. Common Stock
HSTO
| $288K | 0.21% |
+250
| New | +$304K |
2017 Q2
0 quarters
|
|
|
EIGR
57
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $284K | 0.2% |
1,199
| – | – |
2016 Q3
3 quarters
|
|
|
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $262K | 0.19% |
+15,550
| New | +$213K |
2017 Q2
0 quarters
|
|
|
BLCM
59
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $234K | 0.17% |
2,000
| – | – |
2017 Q1
1 quarter
|
|
|
FSTX
60
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $217K | 0.15% |
+400
| New | +$18.5K |
2017 Q2
0 quarters
|
|
|
OBSV
61
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $214K | 0.15% |
25,000
| – | – |
2017 Q1
1 quarter
|
|
62
PDS Biotechnology
PDSB
$81.9M
| $199K | 0.14% |
+970
| New | +$191K |
2017 Q2
0 quarters
|
|
63
DELISTED
Affimed
AFMD
| $190K | 0.14% |
9,250
| – | – |
2017 Q1
1 quarter
|
|
64
DELISTED
Array Biopharma Inc
ARRY
| $167K | 0.12% |
+20,000
| New | +$164K |
2017 Q2
0 quarters
|
|
65
AnaptysBio
ANAB
$1.39B
| $132K | 0.09% |
5,500
+1,000
| +22% | +$25.1K |
2017 Q1
1 quarter
|
|
|
DMK
66
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $127K | 0.09% |
349
-80
| -19% | -$24K |
2017 Q1
1 quarter
|
|
67
DELISTED
Cymabay Therapeutics
CBAY
| $110K | 0.08% |
19,067
-69,000
| -78% | -$294K |
2017 Q1
1 quarter
|
|
|
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
| $88K | 0.06% |
+20,000
| New | +$111K |
2017 Q2
0 quarters
|
|
69
SELLAS Life Sciences
SLS
$2.02B
| $27K | 0.02% |
31
| – | – |
2017 Q1
1 quarter
|
|
|
70
Abeona Therapeutics
ABEO
$253M
| – | – |
-2,701
| Closed | -$338K | – |
|
71
Axsome Therapeutics
AXSM
$8.23B
| – | – |
-55,700
| Closed | -$217K | – |
|
72
Tonix Pharmaceuticals
TNXP
$104M
| – | – |
0
| – | -$93K |
2017 Q1
1 quarter
|
|
73
Palvella Therapeutics
PVLA
$1.73B
| – | – |
-669
| Closed | -$139K | – |
|
|
74
Tvardi Therapeutics
TVRD
$13.5M
| – | – |
-2,648
| Closed | -$1.75M | – |
|
|
CYAD
75
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| – | – |
-12,528
| Closed | -$328K | – |
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2017 Portfolio in Review
As of Q2 2017, DAFNA Capital Management held 83 positions worth $140M, up 19% from $118M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
DAFNA Capital Management deployed $4.55M of net new capital in Q2 2017, opening 9 new positions and adding to 22 existing holdings. Its largest new stake was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was AtriCure, an estimated $2.61M trimmed.
- DAFNA Capital Management's largest Q2 2017 buy was SANGAMO THERAPEUTICS INC: 225,000 shares worth $1.98M.
- DAFNA Capital Management added most to Aerie Pharmaceuticals in Q2 2017, an estimated $2.79M increase.
- DAFNA Capital Management's biggest Q2 2017 reduction was AtriCure, cutting an estimated $2.61M.
- DAFNA Capital Management fully exited Tvardi Therapeutics in Q2 2017, selling an estimated $1.75M.
- DAFNA Capital Management's ten largest holdings make up 48% of its $140M portfolio in Q2 2017.
- DAFNA Capital Management opened 9 new positions and closed 8 in Q2 2017.
- DAFNA Capital Management's portfolio value rose 19% quarter-over-quarter to $140M.
Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.